January 31, 2017
Lilly’s Q4 net income up 61%
Driven by new products, including Trulicity, Cyramza, Jardiance and Taltz, Lilly’s volume-driven significant growth in 2016.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
January 31, 2017
Onxeo and Institue Curie team up to test promising combinations against cancer
Onxeo, an oncology French-based focused drugmaker and a cancer researcher, the Institut Curie, have kicked off several cancer studies, to test the combination of radiotherapy, DNA repair inhibitors and immunotherapy.
January 31, 2017
FDA grants ODD to GenSight’s retinitis pigmentosa drug
GenSight Biologics, a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the Company’s product candidate GS030 for the treatment of retinitis pigmentosa.
January 31, 2017
Ipsen buys gastrointestinal-focused-portfolio Italian company
Ipsen has signed an agreement to take an equity stake in Akkadeas Pharma with an option to take control of the company in the future.
January 31, 2017
India’s health bugdet may rise after minister warns of funding crunch
India’s health ministry is likely to see a substantial increase in funding, after it warned that its programs were short of cash and sought more than $1.2 billion in additional money
January 31, 2017
Teva launches two asthma products in 2017 to compete with GSK
Teva’s two asthma treatments for patients older than 12 has been approved by the US Food and Drug Administration (FDA).
January 31, 2017
US Court rules in Mylan’s favor, another decision against Teva
Israel’s largest drugmaker, Teva, has came up short yet again against a US courts regarding patent infringement cases.
January 31, 2017
US Court rules in Mylan’s favor, another decision against Teva
Israel’s largest drugmaker, Teva, has came up short yet again against a US courts regarding patent infringement cases.
January 31, 2017
European Commission OK’s Novartis’s tuberous sclerosis complex drug
European Commission has approved Novartis’s Votubia (everolimus) dispersible tablets as an adjunctive treatment for patients aged two years and older whose…
January 31, 2017
TiGenix kicks off Sepcell trial to test new pneumonia treatment
TiGenix has enrolled the first patient and treated in a Phase Ib/IIa clinical trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia (CAP).